Chief Medical Officer
Elizabeth Garner joined ObsEva in July 2019, bringing with her over a decade of pharmaceutical development experience, holding roles of increasing strategic responsibility in large and small companies, including Merck, Abbott (AbbVie), Myriad Genetics, and Agile Therapeutics, Inc.
From January 2014 to July 2019, Dr. Garner was Chief Medical Officer of Agile Therapeutics, Inc. and led the company’s clinical development, regulatory, and medical affairs strategies for Agile’s candidate transdermal contraceptive products. She was also instrumental in the company’s successful 2014 Initial Public Offering. Prior to her tenure at Agile, Dr. Garner was Vice President, Medical Affairs, Women’s Health/Preventive Care at Myriad Genetics, where she managed the Key Opinion Leader (KOL) programs, provided medical and scientific input on marketing strategies, and was the company’s media spokesperson. Before that, she was Senior Director at Abbott Laboratories, where she oversaw all clinical aspects of the global Phase 3 endometriosis development program for Orilissa® (elagolix, the first oral GnRH antagonist for treatment of endometriosis).
From 2007 to 2011, Dr. Garner was Associate Director and then Director, Clinical Research at Merck Research Laboratories. As a leader on the human papillomavirus (HPV) vaccine program she was instrumental in achieving successful outcomes on important regulatory submissions. Dr. Garner also served as chair of the Gardasil®9 HPV vaccine program Product Development Team. She was the core presenter for the 2010 FDA Gardasil® Advisory Committee Meeting for which she developed and delivered the company’s presentation that supported FDA’s approval of a gender-neutral anal cancer indication.
Dr. Garner received joint M.D. and M.P.H degrees from Harvard Medical School and the Harvard School of Public Health. She was trained in obstetrics and gynecology at Brigham and Women’s/Massachusetts General Hospitals and completed a fellowship in gynecologic oncology at Brigham and Women’s and Dana Farber Cancer Institute. Prior to entering the pharmaceutical industry, Dr. Garner had several years of experience in academic clinical practice, basic science research in ovarian cancer, and teaching and mentorship at Harvard Medical School. She is also an author on numerous peer-reviewed scientific papers.